Please use this identifier to cite or link to this item: https://doi.org/10.1182/blood-2018-01-829424
Title: Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma
Authors: Song, Tammy Linlin
Nairismagi, Maarja-Liisa
Laurensia, Yurike
Lim, Jing-Quan 
Tan, Jing
Li, Zhi-Mei
Pang, Wan-Lu
Kizhakeyil, Atish
Wijaya, Giovani-Claresta
Huang, Da-Chuan
Nagarajan, Sanjanaa
Chia, Burton Kuan-Hui
Cheah, Daryl
Liu, Yan-Hui
Zhang, Fen
Rao, Hui-Lan
Tang, Tiffany
Wong, Esther Kam-Yin
Bei, Jin-Xin
Iqbal, Jabed
Grigoropoulos, Nicholas-Francis
Ng, Siok-Bian 
Chng, Wee-Joo 
Teh, Bin-Tean 
Tan, Soo-Yong
Verma, Navin Kumar
Fan, Hao 
Lim, Soon-Thye
Ong, Choon-Kiat 
Keywords: Science & Technology
Life Sciences & Biomedicine
Hematology
PERIPHERAL T-CELL
CLASSICAL HODGKIN LYMPHOMA
DEATH LIGAND 1
RECURRENT MUTATIONS
SOMATIC MUTATIONS
LEUKEMIC TRANSFORMATION
GENETIC ALTERATIONS
SIGNALING PATHWAYS
JAK-STAT
BLOCKADE
Issue Date: 13-Sep-2018
Publisher: AMER SOC HEMATOLOGY
Citation: Song, Tammy Linlin, Nairismagi, Maarja-Liisa, Laurensia, Yurike, Lim, Jing-Quan, Tan, Jing, Li, Zhi-Mei, Pang, Wan-Lu, Kizhakeyil, Atish, Wijaya, Giovani-Claresta, Huang, Da-Chuan, Nagarajan, Sanjanaa, Chia, Burton Kuan-Hui, Cheah, Daryl, Liu, Yan-Hui, Zhang, Fen, Rao, Hui-Lan, Tang, Tiffany, Wong, Esther Kam-Yin, Bei, Jin-Xin, Iqbal, Jabed, Grigoropoulos, Nicholas-Francis, Ng, Siok-Bian, Chng, Wee-Joo, Teh, Bin-Tean, Tan, Soo-Yong, Verma, Navin Kumar, Fan, Hao, Lim, Soon-Thye, Ong, Choon-Kiat (2018-09-13). Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. BLOOD 132 (11) : 1146-1158. ScholarBank@NUS Repository. https://doi.org/10.1182/blood-2018-01-829424
Abstract: Mature T-cell lymphomas, including peripheral T-cell lymphoma (PTCL) and extranodal NK/T-cell lymphoma (NKTL), represent a heterogeneous group of non-Hodgkin lymphomas with dismal outcomes and limited treatment options. To determine the extent of involvement of the JAK/STAT pathway in this malignancy, we performed targeted capture sequencing of 188 genes in this pathway in 171 PTCL and NKTL cases. A total of 272 nonsynonymous somatic mutations in 101 genes were identified in 73% of the samples, including 258 single-nucleotide variants and 14 insertions or deletions. Recurrent mutations were most frequently located in STAT3 and TP53 (15%), followed by JAK3 and JAK1 (6%) and SOCS1 (4%). A high prevalence of STAT3 mutation (21%) was observed specifically in NKTL. Novel STAT3 mutations (p.D427H, E616G, p.E616K, and p.E696K) were shown to increase STAT3 phosphorylation and transcriptional activity of STAT3 in the absence of cytokine, in which p.E616K induced programmed cell death-ligand 1 (PD-L1) expression by robust binding of activated STAT3 to the PD-L1 gene promoter. Consistent with these findings, PD-L1 was overexpressed in NKTL cell lines harboring hotspot STAT3 mutations, and similar findings were observed by the overexpression of p.E616K and p.E616G in the STAT3 wild-type NKTL cell line. Conversely, STAT3 silencing and inhibition decreased PD-L1 expression in STAT3 mutant NKTL cell lines. In NKTL tumors, STAT3 activation correlated significantly with PD-L1 expression. We demonstrated that STAT3 activation confers high PD-L1 expression, which may promote tumor immune evasion. The combination of PD-1/PD-L1 antibodies and STAT3 inhibitors might be a promising therapeutic approach for NKTL, and possibly PTCL.
Source Title: BLOOD
URI: https://scholarbank.nus.edu.sg/handle/10635/207360
ISSN: 00064971
15280020
DOI: 10.1182/blood-2018-01-829424
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Song TL. Blood 2018. STAT3 drives PDL1 in ENKTL.pdfPublished version1.37 MBAdobe PDF

CLOSED

Published

SCOPUSTM   
Citations

108
checked on Jan 18, 2022

Page view(s)

33
checked on Jan 20, 2022

Download(s)

1
checked on Jan 20, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.